A Systematic Review and Meta-Analysis for the Association of Gene Polymorphisms in RAN with Cancer Risk
Table 2
The genotype frequency distribution of RAN SNPs in enrolled studies.
Ref. no.
Year
Cancer type
SNPa
Sample size
Case
Control
Included in meta-analysis
Case
Control
Wild homozygote
Heterozygote
Variant homozygote
Wild homozygote
Heterozygote
Variant homozygote
1
2008
Bladder cancer
rs14035 C>T
746
746
348
329
58
318
351
63
0.013
Nob
2
2008
RCC
rs14035 C>T
279
278
143
110
23
129
125
24
0.415
Yes
3
2010
Lung cancer
rs14035 C>T
100
100
65
23
5
52
33
5
0.937
Yes
4
2012
HCC
rs14035 C>T
560
560
376
160
24
390
160
10
0.162
Yes
rs3803012 A>G
560
560
508
52
0
512
48
0
0.289
Yes
5
2012
HNC
rs3803012 A>G
397
900
344
45
2
799
91
2
0.725
Yes
6
2013
HCC
rs3803012 A>G
1300
2688
1158
95
3
2450
227
1
0.066
Yes
7
2013
Cervical cancer
rs3803012 A>G
1486
1549
1325
141
5
1397
129
3
0.990
Yes
8
2013
Breast cancer
rs3809142 C>T
1792
1867
602
232
28
615
239
32
0.149
Noc
rs3803012 A>G
1792
1867
766
92
12
772
107
5
0.539
Yes
rs7301722 C>A
1792
1867
881
733
131
966
716
174
0.015
Nob/c
9
2015
CRC
rs14035 C>T
408
400
267
128
13
233
150
17
0.240
Yes
10
2015
Larynx cancer
rs14035 C>T
135
170
73
32
5
67
93
10
0.002
Nob
11
2016
HCC
rs14035 C>T
147
229
98
42
7
137
69
3
0.080
Yes
12
2017
HCC
rs3803012 A>G
312
320
250
56
6
260
55
5
0.298
Yes
Note: RCC, renal cell carcinoma; HCC, hepatocellular carcinoma; HNC, head and neck cancer; CRC, colorectal cancer; , Hardy-Weinberg equilibrium in the control group. aAncestral alleles were referenced in NCBI database. bExcluded due to not being in accordance with HWE. cExcluded due to the limited number of this locus. The results are in italics if .